Jim Cramer’s Charitable Trust Plans to Trim Cardinal Health and Eli Lilly

Jim Cramer’s Charitable Trust plans to reduce its holdings in Cardinal Health (CAH) and Eli Lilly (LLY) after both stocks rose over 20% since late September. The trust will sell 50 CAH shares at ~$273 each and 10 LLY shares at ~$1,420 each, reducing their portfolio weightings. Both companies recently reported stronger-than-expected earnings and raised outlooks.

Original reporting
Published Nov 7, 2026, 2:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 3:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jim Cramer’s Charitable Trust Plans to Trim Cardinal Health and Eli Lilly — source image
Decision brief

The 30-second read

$CAHBearishLow
01

Why it matters

The fund’s trimming may cause short‑term price pressure but the continued ownership indicates no fundamental concern.

02

Market read

Fund rebalancing could nudge both stocks lower in the short term, but broader market impact is limited.

03

What to watch

Both companies recently posted strong earnings, which could offset the impact of the trust’s modest sell.

Relevance 4/10Novelty 4/10Timing: after market today

Background

Jim Cramer’s Charitable Trust is adjusting its health‑care exposure after recent strong price gains in Cardinal Health and Eli Lilly.

Company-level read

Ticker impact

$CAHBearishMedium confidence
Context

Jim Cramer’s Charitable Trust announced it will sell 50 shares of Cardinal Health, reducing its weighting to 2.75%.

Expected impact

likely slight downward pressure as the fund reduces its stake

Evidence & confidence

A known large investor is trimming its position; the market often reacts with modest price dips.

$LLYBearishMedium confidence
Context

The trust plans to sell 10 shares of Eli Lilly, cutting its weighting to 2.6% while keeping a sizable holding.

Expected impact

likely slight downward pressure as the fund reduces exposure

Evidence & confidence

Even a small sell from a high‑profile fund can influence short‑term sentiment.

Market effects

Health‑care sector may see modest headwinds as a prominent fund trims exposure.

U.S. equities could see slight softening in health‑care stocks.

Limited to U.S. health‑care equities; no broader global effect.

Counterpoint

The trust’s continued holding suggests confidence; the sell may be a tactical rebalancing rather than a negative signal.

Key entities

  • Jim Cramer’s Charitable Trust

    A charitable trust managed by media personality Jim Cramer.

  • Cardinal Health

    U.S. health‑care services and products provider.

  • Eli Lilly

    Pharmaceutical company.

Related articles

$ROG.SWMedAI 8/10

Roche Secures FDA Approval for Wilserdly in Advanced Breast Cancer Treatment

Roche (RHHBY) received FDA approval for Wilserdly (giredestrant), an oral treatment for advanced breast cancer, in combination with Novartis' Afinitor. The drug is Roche's first US-approved treatment of its kind and could significantly boost future sales. Roche is also awaiting FDA decision for earlier-stage use. Competitors like AstraZeneca (AZN) and Eli Lilly (LLY) are developing similar treatments.

$LLYHighAI 9/10

Lilly agrees to acquire Calytrix Bio for $1.5bn

Eli Lilly (LLY) will acquire Calytrix Bio for up to $1.5bn to advance a biparatopic antibody for myeloproliferative neoplasms. The deal includes an upfront payment and milestone-based payouts. Calytrix Bio's therapy targets mutant calreticulin-driven diseases, aiming to modify the disease course. According to Calytrix Bio, the acquisition accelerates their vision to benefit patients.

$LLYMed

TGA registers new GLP-1 pill

The TGA has approved Lilly's GLP-1 pill, Foundayo, for obesity and type 2 diabetes treatment. Lilly expects stock to arrive soon, making it the first GLP-1 pill available in Australia. This follows the TGA's approval of Novo Nordisk's Wegovy tablet.

$LLYMed

Retatrutide Cut Sleep Apnea Breathing Events Up to 60.6% in Lilly Trial, but the Weekly Shot Remains Unapproved

Eli Lilly reported that retatrutide, an experimental weekly injection, reduced breathing interruptions in sleep apnea patients by up to 60.6% in an 80-week trial. The drug also showed a 48.1% reduction in a separate trial involving Type 2 diabetes patients. Lilly plans to seek FDA approval in early 2027, but the drug is not yet approved for any use. The results were presented at ObesityWeek 2026, with full peer-reviewed data not yet published.